top of page
Where Science Sparks Business in Medicines
Co-producers
BioVerse Episode 18 - China-to-West: Deals Shaping the Immuno-Oncology Landscape
Search video...
BioVerse Episode 18 - China-to-West: Deals Shaping the Immuno-Oncology Landscape
58:38
Play Video
BioVerse Episode 17 - JPM2025 Recap - News, Trends, Sentiment, and China Trade
01:14:15
Play Video
BioVerse Episode 16 - Asian Biotechies Walk Into BioVerse to Review 2024 in Biotech
01:28:05
Play Video
BioVerse Episode 15 - M&A, The Ultimate Exit of Biotechs
01:17:13
Play Video
BioVerse Episode 14 - The Current Global Trends In Biotech IPOs
01:23:16
Play Video
BioVerse Episode 13 - The Current Trends of R&D and Deal-making in Immunology & Inflammation
01:08:37
Play Video
BioVerse episode 12 - Artificial Intelligence in Drug Development
01:31:54
Play Video
BioVerse Episode 11 - China Biotech Out-licensing 2.0: Global Vision, Local Execution (Chinese)
02:24:51
Play Video
Bioverse Episode 10 - The Winners, Losers, and Dark Horses of ASCO24 & BIO2024 tidbits
01:41:35
Play Video
Bioverse Episode 9 - The Essential Role of CMC in ADC, Radiopharmaceutical, and Cell & Gene Therapy
01:03:18
Play Video
Bioverse episode 8 - Recap of AACR 2024
01:33:18
Play Video
Bioverse episode 7 - Leverage Commercial Lens to Enable Successful Drug Development and Deal-making
01:11:12
Play Video
Bioverse episode 6 - Physician Scientists' Checklists to Conduct Successful Clinical Development
49:16
Play Video
Bioverse episode 5 - JPM24 Recap and 2004 global outlook, from the lens of China biotech
59:36
Play Video
BioVerse episode 4 - How to survive and thrive in a biotech winter, a chat with Les Funtleyder
01:01:03
Play Video
BioVerse episode 3 - The Past, Current Status, and Future of Cross-border ADC deal-making
01:13:20
Play Video
BioVerse episode 2 - A conversation with Chris Sheldon, the BD chief of GSK
01:03:47
Play Video
BioVerse episode 1 - Catherine Pearce, CinCor Pharma, and BioTech M&A
01:03:23
Play Video
bottom of page